Flagship acquisition memo for Remedy Hospitals — a 150-bed distressed Hyderabad secondary-care platform acquired at 11.8x FY26 EBITDA (30% sector discount). 80% control buyout, debt refinancing, and 3-year turnaround applying NASA's five-lever operational playbook to drive FY29 EBITDA to ₹13.5 Cr.
NASA Hospitals' core thesis: India's secondary-care hospital market is highly fragmented with 10,000+ independent 50–150 bed hospitals, many operating under financial distress due to debt burden, management inefficiency, and reliance on general-practitioner clinical positioning. Corporate chains like Apollo and Max have consolidated the top tier of the market (tertiary, 300+ bed multi-specialty) but the mid-market specialty segment remains structurally under-professionalised.
NASA acquires these distressed assets at deep discounts (8–10× EBITDA vs sector 15–16×), applies a specialty-first operational playbook, and consolidates into a 1,000-bed platform over 5 years. The exit is IPO or strategic sale at stabilised sector multiples of 16–18×, producing a 2.0–3.0× bid-ask arbitrage on platform creation alone — before any organic EBITDA growth is layered in.
Crucially, capital is deployed into operations and consolidation — not real estate. NASA leases hospital real estate (rather than owning it) to maintain high ROCE. This asset-light posture is what differentiates NASA from traditional hospital operators and supports the 25-30% ROCE target.
Remedy Hospitals is NASA's lead pipeline acquisition and the flagship deal of the $40M platform raise. 150 beds, Hyderabad-based, distressed secondary-care platform with a ₹24.4 Cr debt burden (3.6× leverage) creating refinancing urgency. The deal structure reflects NASA's consolidation playbook applied at its sharpest.
| Transaction Component | ₹ Cr | Rationale |
|---|---|---|
| Promoter Buyout (80%) | 10 | Majority control; promoters retain 20% for alignment and legacy |
| Debt Refinancing | 15 | Eliminate ₹24.4 Cr distressed debt at 18% → replace with ₹15 Cr at 12% (save ₹3.8 Cr annual interest) |
| Working Capital | 10 | Normalize DSO from 90→60 days; transition-period operating cushion |
| Capex (Equipment) | 5 | CT/ICU upgrades; reduce maintenance drag by 30% |
| NASA Platform Consolidation | 15 | Pre-fund consolidation of NASA's existing 300-bed platform (3 hospitals) |
| Total Equity Required | 55 | EV: ₹80 Cr @ 11.8× FY26E EBITDA (~30% sector discount) |
| Phase | Period | Lever | ₹ Cr | EBITDA |
|---|---|---|---|---|
| Entry | FY26 | — | — | ₹6.8 Cr (23%) |
| Phase 1: Stabilisation (FY27) | ||||
| Lever 1 | FY27 | Interest savings (₹24.4 Cr @ 18% → ₹15 Cr @ 12%) | +1.2 | — |
| Lever 2 | FY27 | Procurement optimisation (12% cost reduction) | +0.6 | — |
| Lever 3 | FY27 | RPT elimination (remove related-party markups) | +0.4 | — |
| Subtotal | FY27 | — | +2.2 | ₹9.0 Cr (25%) |
| Phase 2: Growth (FY28) | ||||
| Lever 4 | FY28 | ARPOB expansion (case-mix shift to higher acuity) | — | Revenue: ₹48 Cr |
| Subtotal | FY28 | — | — | ₹11 Cr (23%) |
| Phase 3: Scale (FY29) | ||||
| Lever 5 | FY29 | Occupancy lift (60% → 75% via specialty positioning) | +3.0 | Revenue: ₹55 Cr |
| Lever 6 | FY29 | NASA network tertiary referrals (1,200 annual) | +2.0 | — |
| Subtotal | FY29 | — | — | ₹13.5 Cr (24–25%) |
| Roll-Up Portfolio | FY29 | Remedy + NASA's existing 3 hospitals (350 beds) | — | ₹27 Cr (25%) |
NASA's operating playbook deploys five integrated levers in sequence at each newly-acquired hospital:
| Phase | Timing | Lever | EBITDA Impact |
|---|---|---|---|
| 1. Stabilisation | Months 0–6 | Debt refinancing (18% → 12% rate). RPT vendor markup elimination. Governance & compliance upgrade. | +15–25% margin expansion |
| 2. Procurement | Months 3–9 | Integrate with NASA central procurement for pharma, consumables, medical devices. | 12% cost reduction |
| 3. Specialty Focus | Months 6–12 | Shift case mix from general to single-specialty (Neuro, Spine, Ortho, or CC). Recruit specialty clinicians. Rebrand. | ARPOB +30–40% |
| 4. Occupancy Lift | Months 9–18 | Referral engine from NASA network. Targeted insurance empanelment. Specialty-specific marketing. | Occupancy 60% → 75% |
| 5. Cross-Sell | Months 12+ | Tertiary referrals to other NASA hospitals (e.g., Ortho patient needing Spine care). | Incremental ARPOB lift |
Remedy's exit is tied to the NASA platform IPO at FY29–FY30, at which point Remedy is one of ~8–10 hospitals in a 1,000-bed platform. Remedy itself contributes ~₹13.5 Cr of FY29 EBITDA into the consolidated ₹50–60 Cr platform EBITDA pool.
Remedy-level exit math: at a 16× exit multiple on Remedy's standalone ₹13.5 Cr FY29 EBITDA, implied Remedy EV is ~₹216 Cr — a 2.7× return on the ₹80 Cr entry EV over ~4 years.
Platform uplift: Consolidation into a 1,000-bed listed platform typically commands additional multiple expansion (platform premium over standalone asset value), creating further upside at exit.
Secondary path: Strategic sale of Remedy as a carve-out to a regional operator — lower return but available as downside protection if platform IPO conditions are unfavourable.
Transaction structure, 3-year P&L trajectory, EBITDA bridge, balance sheet, cash flow, and return scenarios on the Remedy Financials page.